On Thursday, August 3, 2017, the Arthritis Advisory Committee (AAC) supported by a vote of 10-Yes to 1-No, with no abstentions, the approval of XELJANZ (tofacitinib) tablets and XELJANZ XR (tofacitinib) extended-release (XR) tablets, submitted by Pfizer Inc. (Pfizer), for the treatment of adult patients with active psoriatic arthritis.
Back to All Events
Earlier Event: August 2
Arthritis Advisory Committee
Later Event: August 3
Advisory Committee on Heritable Disorders in Newborns and Children